XTL Biopharma Finalizes Purchase of Psyga Bio, Deepening Focus on Psychedelic Therapies

XTL Biopharmaceuticals Ltd. announced the completion of its acquisition of Psyga Bio Ltd., positioning psychedelic therapies as the company’s sole core focus.

Psyga Bio offers a pipeline of psilocybin‑based and other psychedelic compounds aimed at severe mental‑health disorders, including treatment‑resistant depression, post‑traumatic stress disorder (PTSD), anorexia, and addiction.

The firm also operates a licensed pharmaceutical manufacturing facility dedicated to cultivating, extracting, isolating, and formulating medical‑grade psychedelic active‑pharmaceutical ingredients (APIs), granting XTL operational independence and large‑scale commercialization capabilities.

With growing market interest in psychedelic treatments, XTL believes the combined entity will seize significant opportunities.

Under the pre‑existing agreement, XTL acquired 270,000 shares of Psyga, representing approximately 83.40% of its fully diluted share capital.

The purchase was executed through the issuance of American Depositary Shares (ADSs), which now account for roughly 33.36% of XTL’s post‑issuance equity; each ADS equals 400 ordinary shares. Psyga shareholders may receive an additional up to 25.02% of XTL’s capital contingent on achieving three defined clinical and commercial milestones.

XTLB’s share price has fluctuated between $2.01 and $10.28 over the past year, closing at $2.73 earlier this week—a 15.68% increase. The stock currently trades at $2.75, up 0.73%.[/p]

Source link